0000000000738620
AUTHOR
J Huang
Evaluation of appendicitis risk prediction models in adults with suspected appendicitis.
Background Appendicitis is the most common general surgical emergency worldwide, but its diagnosis remains challenging. The aim of this study was to determine whether existing risk prediction models can reliably identify patients presenting to hospital in the UK with acute right iliac fossa (RIF) pain who are at low risk of appendicitis. Methods A systematic search was completed to identify all existing appendicitis risk prediction models. Models were validated using UK data from an international prospective cohort study that captured consecutive patients aged 16–45 years presenting to hospital with acute RIF in March to June 2017. The main outcome was best achievable model specificity (pro…
Search for new particles in the two-jet decay channel with the DØ detector
We present the results of a search for the production of new particles decaying into two jets in pp collisions at √s = 1.8 TeV, using the DØ 1992-1995 data set corresponding to 109 pb-1. We exclude at the 95% confidence level the production of excited quarks (q*) with masses below 775 GeV/c2, the most restrictive limit to date. We also exclude standard-model-like W′ (Z′) bosons with masses between 300 and 800 GeV/c2 (400 and 640 GeV/c2). A. W√ boson with mass <786 GeV/c2 has been excluded by previous measurements, and our lower limit is therefore the most stringent to date. © 2004 The American Physical Society.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…